Belimumab (Benlysta) for Lupus Nephritis (online only)
Date: September 23, 2021
Issue #:
1634Summary:
The B-lymphocyte stimulator (BLyS)-specific inhibitor
belimumab (Benlysta– GSK), which was approved
earlier for treatment of active, autoantibody-positive,
nonrenal, systemic lupus erythematosus (SLE), has
now been approved for use in addition to standard
therapy for treatment of active lupus nephritis in
adults. Belimumab is the first drug to be approved in
the US for treatment of both SLE and lupus nephritis.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: Azathioprine belimumab Benlysta Cellcept corticosteroids Cyclophosphamide Cytoxan Imuran Lupkynis Lupus Mycophenolate mofetil Prograf Rituxan Rituximab Tacrolimus voclosporin Source Type: research
More News: Corticosteroid Therapy | Drugs & Pharmacology | Lupus | Nephritis | Prograf | Rituxan | Tacrolimus